Singh Nisha, Mishra Bhuwan B, Bajpai Surabhi, Singh Rakesh K, Tiwari Vinod K
Molecular Immunology Laboratory, Department of Biochemistry, Faculty of Science, Banaras Hindu University, Varanasi 221005, India.
Department of Chemistry, Faculty of Science, Banaras Hindu University, Varanasi 221005, India.
Bioorg Med Chem. 2014 Jan 1;22(1):18-45. doi: 10.1016/j.bmc.2013.11.048. Epub 2013 Dec 4.
The growing incidence of parasitic resistance against generic pentavalent antimonials, specifically for visceral disease in Indian subcontinent, is a serious issue in Leishmania control. Notwithstanding the two treatment alternatives, that is amphotericin B and miltefosine are being effectively used but their high cost and therapeutic complications limit their use in endemic areas. In the absence of a vaccine candidate, identification, and characterization of novel drugs and targets is a major requirement of leishmanial research. This review describes current drug regimens, putative drug targets, numerous natural products that have shown promising antileishmanial activity alongwith some key issues and strategies for future research to control leishmaniasis worldwide.
在印度次大陆，针对普通五价锑剂的寄生虫耐药性日益增加，这在利什曼病控制中是一个严重问题，尤其是在内脏疾病方面。尽管有两种替代治疗药物，即两性霉素B和米替福新正在得到有效使用，但它们的高成本和治疗并发症限制了它们在流行地区的应用。由于缺乏候选疫苗，鉴定和表征新型药物及靶点是利什曼病研究的主要需求。本综述描述了当前的药物治疗方案、假定的药物靶点、众多已显示出有前景的抗利什曼活性的天然产物，以及在全球范围内控制利什曼病未来研究的一些关键问题和策略。
